CTN-0097: Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder

Adam Bisaga, MD
Lead Investigator

New York State Psychiatric Institute
Division on Substance Abuse

Edward V. Nunes, Jr., MD
Lead Investigator

Columbia University College of Physicians and Surgeons and New York State Psychiatric Institute

Inpatient programs are important portals for increasing access to treatment. However, most individuals with opioid use disorder are detoxified but not offered medications to prevent relapse. This randomized-controlled trial will examine whether a rapid-transition protocol to inducting extended release naltrexone (XR-NTX) following detoxification yields a higher proportion of patients successfully receiving the first injection of XR-NTX compared to standard detoxification and naltrexone initiation. This study will also assess facilitators and barriers to implementing rapid XR-NTX initiation. The overall goal is to foster widespread adoption of a 5-7-day protocol for initiation of treatment with XR-NTX at Inpatient/Residential programs.

Funded by the NIH HEAL InitiativeSM.

    Node Involvement

    Lead Node(s):

  • New York Node

  • All Participating Nodes:

  • New York Node